Peterson Joanne L, Phelps Eric D, Doll Mark A, Schaal Shlomit, Ceresa Brian P
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, United States.
Invest Ophthalmol Vis Sci. 2014 May 1;55(5):2870-80. doi: 10.1167/iovs.13-12943.
To provide a comprehensive study of the biological role and therapeutic potential of six endogenous epidermal growth factor receptor (EGFR) ligands in corneal epithelial homeostasis.
Kinetic analysis and dose response curves were performed by using in vitro and in vivo wound-healing assays. Biochemical assays were used to determine receptor expression and activity. Human tears were collected and quantitatively analyzed by multianalyte profiling for endogenous EGFR ligands.
Epidermal growth factor receptor ligands improved wound closure and activated EGFR, but betacellulin (BTC) was the most efficacious promoter of wound healing in vitro. In contrast, only epidermal growth factor (EGF) promoted wound healing in vivo. Human tears from 25 healthy individuals showed EGFR ligands at these average concentrations: EGF at 2053 ± 312.4 pg/mL, BTC at 207 ± 39.4 pg/mL, heparin-binding EGF at 44 ± 5.8 pg/mL, amphiregulin at 509 ± 28.8 pg/mL, transforming growth factor-α at 84 ± 19 pg/mL, and epiregulin at 52 ± 15 pg/mL.
Under unwounded conditions, only EGF was present at concentrations near the ligand's Kd for the receptor, indicating it is the primary mediator of corneal epithelial homeostasis. Other ligands were present but at concentrations 11- to 7500-fold less their Kd, preventing significant ligand binding. Further, the high levels of EGF and its predicted binding preclude receptor occupancy by exogenous ligand and can explain the discrepancy between the in vitro and in vivo data. Therefore, therapeutic use of EGFR ligands may be unpredictable and impractical.
全面研究六种内源性表皮生长因子受体(EGFR)配体在角膜上皮稳态中的生物学作用及治疗潜力。
采用体外和体内伤口愈合试验进行动力学分析和剂量反应曲线研究。运用生化分析方法测定受体表达和活性。收集人泪液,通过多分析物谱分析对内源性EGFR配体进行定量分析。
表皮生长因子受体配体可改善伤口闭合并激活EGFR,但β细胞素(BTC)是体外伤口愈合最有效的促进剂。相比之下,只有表皮生长因子(EGF)在体内促进伤口愈合。25名健康个体的人泪液中EGFR配体的平均浓度如下:EGF为2053±312.4 pg/mL,BTC为207±39.4 pg/mL,肝素结合EGF为44±5.8 pg/mL,双调蛋白为509±28.8 pg/mL,转化生长因子-α为84±19 pg/mL,上皮调节素为52±15 pg/mL。
在未受伤条件下,只有EGF的浓度接近其与受体的解离常数(Kd),表明它是角膜上皮稳态的主要调节因子。其他配体虽有存在,但浓度比其Kd低11至7500倍,无法实现显著的配体结合。此外,EGF的高浓度及其预期的结合情况会阻止外源性配体与受体结合,这可以解释体外和体内数据之间的差异。因此,EGFR配体的治疗用途可能不可预测且不切实际。